Through PPAR-γ transactivation and trans-repression, by altering the expression of related genes to promote fatty acids storage in adipocytes, and consequently prioritizing the oxidation of carbohydrates, more specifically glucose, for cellular energy supply, TZDs are primarily employed in the treatment of type 2 diabetes (T2D) as insulin sensitizers. Here, INS is linked to type 2 diabetes mellitus.